


Bioactivation of Fluorinated 2-Aryl-benzothiazole Antitumor Molecules by Human Cytochrome P450s 1A1 and 2W1 and Deactivation by Cytochrome P450 2S1

Kai Wang and F. Peter Guengerich*

Department of Biochemistry and Center in Molecular Toxicology, Vanderbilt University, School of Medicine, 638 Robinson Research Building, 2200 Pierce Avenue, Nashville, Tennessee 37232-0146, United States

S Supporting Information

ABSTRACT: Both 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (SF 203) and 5-fluoro-2-(3,4-dimethoxyphenyl)-benzothiazole (GW 610) contain the benzothiazole pharmacophore and possess potent and selective in vitro antitumor properties. Prior studies suggested the involvement of cytochrome P450 (P450) 1A1 and 2W1-mediated bioactivation in the antitumor activities and P450 2S1-mediated deactivation of SF 203 and GW 610. In the present study, the biotransformation pathways of SF 203 and GW 610 by P450s 1A1, 2W1, and 2S1 were investigated, and the catalytic parameters of P450 1A1- and 2W1-catalyzed oxidation were determined in steady-state kinetic studies. The oxidations of SF 203 catalyzed by P450s 1A1 and 2W1 yielded different products, and the formation of a hydroxylamine was observed for the first time in the latter process. Liquid chromatography–mass spectrometry (LC-MS) analysis with the synthetic hydroxylamine and also a P450 2W1/SF 203 incubation mixture indicated the formation of dGuo adduct via a putative nitrenium intermediate. P450 2W1-catalyzed oxidation of GW 610 was 5-fold more efficient than the P450 1A1-catalyzed reaction. GW 610 underwent a two-step oxidation process catalyzed by P450 1A1 or 2W1: a regioselective *O*-demethylation and a further hydroxylation. Glutathione (GSH) conjugates of SF 203 and GW 610, presumably through a quinoneimine and a 1,2-quinone intermediate, respectively, were detected. These results demonstrate that human P450s 1A1 and 2W1 mediate SF 203 and GW 610 bioactivation to reactive intermediates and lead to GSH conjugates and a dGuo adduct, which may account for the antitumor activities of SF 203 and GW 610 and also be involved in cell toxicity. P450 2S1 can catalyze the reduction of the hydroxylamine to the amine SF 203 under anaerobic conditions and, to a lesser extent, under aerobic conditions, thus attenuating the anticancer activity.



INTRODUCTION

P450 enzymes catalyze the oxidation and reduction of a variety of drugs, carcinogens, steroids, lipids, and other organic molecules.^{1,2} The Human Genome Project has identified 57 P450 genes.³ About one-fourth are still classified as “orphan” P450s because their functions remain largely unknown.⁴ P450s 2W1 and 2S1 remain in this category, and a number of carcinogens were shown to be activated by P450 2W1 but not P450 2S1 when heterologously expressed in this laboratory.⁵ The only repeatedly demonstrated reaction of P450 2S1 to date is the reduction of a di-*N*-oxide, AQ4N, to its amino derivative AQ4 [1,4-bis([2-(dimethylamino)ethyl]amino)-5,8-dehydroxanthracene-9,10-dione] under anaerobic conditions.^{6,7} P450 2W1 has been found to be overexpressed in tumor cells, especially in colon tumor cells, with only low or undetectable expression levels in other tissues.^{8,9} Prior studies have also


reported that the expression level of P450 2W1 is an independent prognostic factor in colon cancer, with high expression levels associated with poor clinical outcome.¹⁰ The functions of these two P450s are still not well understood, although P450 2W1 has been shown to have activity toward some drugs and lysophospholipids.^{5,33}

In the screening of 2-arylbenzothiazoles for anticancer activity, a number of molecules have been discovered with novel anticancer mechanisms, 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (SF 203) and 5-fluoro-2-(3,4-dimethoxyphenyl)-benzothiazole (GW 610) being two promising drug candidates.¹¹ SF 203 showed antiproliferative potency in sensitive human breast and ovarian cancer cell lines ($GI_{50} < 1$

Received: May 1, 2012

Published: June 26, 2012

Scheme 1. Synthesis of GW 610, SF 203, and Their Putative Metabolites



nM for MCF-7, MDA 468, and IGROV-1 cells) and emerged as a lead compound, currently in phase 1 clinical trials in the United Kingdom.^{12,13} The results of coinubation of 2-(4-amino-3-methyl-phenyl)benzothiazole (DF 203, an anticancer agent discovered earlier, yielding inactive metabolites that led to the discovery of SF 203¹²) with α -naphthoflavone, a P450 1A1 inhibitor, showed inhibition of anticancer activity and revealed a role for P450 1A1 in the anticancer activity of the benzothiazoles.¹⁴ The involvement of P450 1A1 was reported for SF 203 bioactivation (to generate reactive intermediates to form protein and DNA adducts) in the antitumor process within sensitive cells.^{13,15} P450 1A1 is expressed in fetal liver and in some extrahepatic adult human tissues but not at appreciable levels in adult liver.^{16,17} SF 203 acts as both a substrate and an inducer of P450 1A1, the latter process involving binding to the aryl hydrocarbon receptor.¹⁸

Although P450 1A1 has been shown to be involved in the bioactivation of SF 203, the products are still uncharacterized. In a prior study of the metabolism of SF 203 in human B-lymphoblastoid cells expressing P450 1A1, 1B1, and 1A2, respectively,¹³ P450 1A1 exhibited the highest level of metabolic capacity. However, no chemical structures of the metabolites were determined.

More recently, GW 610, a dimethoxyphenyl benzothiazole derivative, was discovered to exhibit potent (GI₅₀ < 0.1 nM) and selective in vitro inhibitory activity against colon, lung, and breast cancer cell lines.¹⁹ Even less information has been

reported on the metabolism of GW 610. GW 610,¹⁹ like SF 203,¹⁸ can induce P450 1A1 in breast cancer cell lines (MCF-7 and MDA 468). However, P450 1A1 was neither highly expressed nor could be induced in the sensitive colon cancer cell lines KM12 and HCC2998. The conclusion was reached that the antitumor properties of GW 610 were unlikely to depend upon P450 1A1-mediated bioactivation alone. Demethylation was proposed as an initial mechanistic step in the antitumor process,¹¹ although no evidence was provided.

The suggestion has been made that P450 1A1-mediated metabolism of SF 203 and GW 610 is involved in their anticancer activities.²⁰ In addition, P450 2W1-mediated bioactivation was concluded to be essential for GW 610 activation in colon cancer cells.²⁰ In contrast, SF 203 and GW 610 showed enhanced growth inhibition effects in P450 2S1 knock-down cancer cells; that is, P450 2S1 deactivated these two anticancer molecules.²⁰

The biotransformation of GW 610 and SF 203 by P450 1A1, 2W1, and 2S1 plays a critical role in their potent and selective antitumor properties, as well as in any toxicity associated with these molecules. Knowledge of the biotransformation pathways is important in understanding the antitumor activity and improvement of drug efficacy. In this article, we report results on the biotransformation pathways of GW 610 and SF 203 mediated by P450s 1A1, 2W1, and 2S1, characterization of the major oxidation products, and evidence for GSH conjugates and dGuo adduct formation from the reactive products.

EXPERIMENTAL PROCEDURES

All commercially obtained solvents and other chemicals were used directly without further purification. 2-Amino-5-fluorobenzothiazole and 2-phenylbenzothiazole were purchased from Alfa Aesar (Ward Hill, MA). 3-Methyl-4-nitrobenzoic acid was purchased from Sigma Aldrich (St. Louis, MO). One- and two-dimensional NMR spectroscopy data were obtained with 400 or 600 MHz Bruker NMR spectrometers, in the solvents noted, in the Vanderbilt facility. UV spectra were obtained (online) with a Waters Acquity ultra performance liquid chromatography (UPLC) system equipped with a photodiode array detector (Waters, Milford, MA).

Chemical Synthesis (Scheme 1). *Bis(aminofluorophenyl) Disulfide (2)*. The title compound was prepared using a known procedure.¹² 2-Amino-5-fluorobenzothiazole (**1**) (0.125 g, 0.74 mmol) was added to a solution of KOH (0.625 g) in H₂O (4 mL), and the resulting mixture was heated to reflux. After 3 h, a clear solution was formed, and the solution was stirred under reflux for another 2 h. The solution was cooled to room temperature and acidified to pH 6 by the addition of CH₃CO₂H. H₂O (1 mL) was added to the mixture, which was then stirred overnight. The solid precipitate was collected and purified by flash column chromatography on silica gel (CH₂Cl₂:hexanes, 3:1, v/v). Compound **2** was obtained as a pale yellow solid (0.077 g, 73% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.05 (dd, *J* = 8.5, 6.5 Hz, 2H, H-6), 6.41 (dd, *J* = 10.5, 2.6 Hz, 2H, H-3), 6.29 (td, *J* = 8.5, 2.6 Hz, 2H, H-5), 4.47 (br s, 4H, NH₂).

General Method for the Synthesis of GW 610 and Its Monodemethylated Analogues, 4a–c. Compounds **4a–c** were synthesized by using a previously reported method.¹¹ Each disubstituted benzaldehyde (**3a–c**; 0.20 mmol), *p*-toluenesulfonic acid monohydrate (0.040 mmol), and triphenylphosphine (0.20 mmol) was added to a solution of **2** in toluene (5 mL). The resulting mixture was stirred and heated under reflux for 24 h. After each mixture was cooled to room temperature, the solvent was removed in vacuo. Flash chromatography (CH₂Cl₂, 100%) afforded corresponding **4a–c** as white solids in yields of 68–87%.

5-Fluoro-2-(3,4-dimethoxyphenyl)-benzothiazole (4a, GW 610). Compound **4a** was prepared from **2** and veratraldehyde (68% yield): UV λ_{max} 331 nm. ¹H NMR (400 MHz, CDCl₃): δ 7.80 (dd, *J* = 8.8, 5.1 Hz, 1H, H-7), 7.73 (dd, *J* = 9.6, 2.3 Hz, 1H, H-4), 7.72 (d, *J* = 2.3 Hz, 1H, H-2'), 7.60 (dd, *J* = 8.4, 2.1 Hz, 1H, H-6'), 7.14 (td, *J* = 8.8, 2.5 Hz, 1H, H-6), 6.96 (d, *J* = 8.4 Hz, 1H, H-5'), 4.03 (s, 3H, OCH₃-3'), 3.97 (s, 3H, OCH₃-4'). HRMS *m/z* calcd for C₁₅H₁₃FN₂S (MH⁺), 290.0646; found, 290.0643.

5-Fluoro-2-(3-hydroxy-4-methoxyphenyl)-benzothiazole (4b). Compound **4b** was prepared from **2** and 3-hydroxy-4-dimethoxybenzaldehyde (87% yield): UV λ_{max} 331 nm. ¹H NMR (400 MHz, CDCl₃): δ 7.79 (dd, *J* = 8.8, 5.1 Hz, 1H, H-7), 7.72 (dd, *J* = 9.6, 2.5 Hz, 1H, H-4), 7.65 (m, 2H, H-2', H-6'), 7.13 (td, *J* = 8.8, 2.5 Hz, 1H, H-6), 6.95 (d, *J* = 9.0 Hz, 1H, H-5'), 5.73 (br s, 1H, OH-3'), 3.98 (s, 3H, OCH₃-4'). HRMS *m/z* calcd for C₁₄H₁₁FN₂O₂S (MH⁺), 276.0489; found, 276.0487.

5-Fluoro-2-(4-hydroxy-3-methoxyphenyl)-benzothiazole (4c). Compound **4c** was prepared from **2** and vanillin (83% yield): UV λ_{max} 331 nm. ¹H NMR (400 MHz, CDCl₃): δ 7.79 (dd, *J* = 8.8, 5.1 Hz, 1H, H-7), 7.72 (d, *J* = 2.1 Hz, 1H, H-2'), 7.71 (dd, *J* = 10.2, 2.1 Hz, 1H, H-4), 7.53 (dd, *J* = 8.3, 2.0 Hz, 1H, H-6'), 7.13 (td, *J* = 8.8, 2.5 Hz, 1H, H-6), 7.01 (d, *J* = 8.3 Hz, 1H, H-5'), 5.95 (br s, 1H, OH-4'), 4.04 (s, 3H, OCH₃-3'). HRMS *m/z* calcd for C₁₄H₁₁FN₂O₂S (MH⁺), 276.0489; found, 276.0479.

3-Methyl-4-nitrobenzoyl Chloride (6). 3-Methyl-4-nitrobenzoic acid (0.60 g), thionyl chloride (3 mL), and DMF (0.05 mL) were heated under reflux for 4 h, cooled, and concentrated in vacuo. The residue was slurried twice with hexanes and concentrated to yield **6** as a yellow solid, which was used immediately to the next reaction.

Bis[4-fluoro-2-(3-methyl-4-nitrobenzoyl)aminophenyl] Disulfide (7). Compound **7** was synthesized as reported previously.¹² Compound **6** (25 mg, 0.125 mmol) was added to a solution of **2** (15 mg, 0.053 mmol) in anhydrous pyridine (3 mL). The reaction mixture was stirred and heated under reflux for 30 min and then poured into H₂O (15 mL). The precipitate was collected and washed

with H₂O to afford **7** as a pale yellow solid (12 mg, 75%). ¹H NMR (400 MHz, CDCl₃): δ 8.87 (brs, 2H, NH), 8.18 (dd, *J* = 11.0, 2.8 Hz, 2H, H-3), 8.01 (d, *J* = 8.4 Hz, 2H, H-5'), 7.73 (s, 2H, H-2'), 7.53 (dd, *J* = 8.4, 1.8 Hz, 2H, H-6'), 7.47 (dd, *J* = 8.6, 6.2 Hz, 2H, H-6), 6.67 (td, *J* = 8.1, 2.8 Hz, 2H, H-5), 2.68 (s, 6H, CH₃).

2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole (8, 5F 203). Compound **8** was synthesized as reported elsewhere.¹² To a solution of concentrated HCl (1 mL), C₂H₅OH (2 mL), and H₂O (0.2 mL) was added the disulfide **7** (12 mg) and SnCl₂·2H₂O (80 mg). The resulting mixture was stirred and heated under reflux for 15 h and allowed to cool, and then, H₂O (7.5 mL) and NaOH (0.40 g) were added slowly. The mixture was stirred for 1 h, after which the precipitate was collected and washed with H₂O (5 mL). Flash chromatography (CH₂Cl₂, 100%) afforded **8** as a pale yellow solid (6.9 mg, 68%). UV λ_{max} 347 nm. ¹H NMR (400 MHz, CDCl₃): δ 7.83 (s, 1H, H-2'), 7.79–7.72 (m, 2H, H-7, H-6'), 7.69 (dd, *J* = 9.7, 2.5 Hz, 1H, H-4), 7.09 (td, *J* = 8.8, 2.5 Hz, 1H, H-6), 6.73 (d, *J* = 8.3 Hz, 1H, H-5'), 2.25 (s, 3H, CH₃). HRMS *m/z* calcd for C₁₄H₁₂FN₂S (MH⁺), 259.0700; found, 259.0689.

2-(3-Methyl-4-nitrophenyl)-5-fluorobenzothiazole (9). To a solution of the disulfide **7** (29 mg, 0.048 mmol) in toluene (3 mL) were added triphenylphosphine (12.7 mg, 0.048 mmol) and *p*-toluenesulfonic acid monohydrate (1.9 mg, 9.7 μmol). The resulting mixture was heated under reflux for 24 h. The solvent was removed in vacuo, and flash column chromatography gave **9** as a pale yellow solid (23 mg, 83%). UV λ_{max} 323 nm. ¹H NMR (400 MHz, CDCl₃): δ 8.10 (d, *J* = 8.6 Hz, 1H, H-5'), 8.09 (s, 1H, H-2'), 8.02 (dd, *J* = 8.4, 1.8 Hz, 1H, H-6'), 7.88 (dd, *J* = 8.8, 5.0 Hz, 1H, H-7), 7.80 (dd, *J* = 9.3, 2.5 Hz, 1H, H-4), 7.22 (td, *J* = 8.8, 2.5 Hz, 1H, H-6), 2.72 (s, 3H, CH₃). HRMS *m/z* calcd for C₁₄H₁₀FN₂O₂S (MH⁺), 289.0442; found, 289.0429.

2-(4-Hydroxylamino-3-methylphenyl)-5-fluorobenzothiazole (10) and 2-(3-Methyl-4-nitrosophenyl)-5-fluorobenzothiazole (11). To a solution of **9** (1.4 mg, 4.9 μmol) in THF (3 mL) was added Pd/C (10%, catalyst) and hydrazine hydrate (20 μL) under Ar.²¹ The reaction mixture was stirred at room temperature. After 2 h, the reaction was complete. The solvent was removed in vacuo, and the residue was purified by flash chromatography to afford **10** as a yellow solid (1.1 mg, 83%) (note: the solubility of **10** in CHCl₃ and CH₃OH is very poor). UV λ_{max} 339 nm. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.68 (s, 1H), 8.57 (s, 1H), 8.11 (dd, *J* = 8.7, 5.4 Hz, 1H, H-7), 7.85 (d, *J* = 8.5 Hz, 1H, H-6'), 7.80 (dd, *J* = 8.8, 2.4 Hz, 1H, H-4), 7.75 (s, 1H, H-2'), 7.31 (td, *J* = 8.8, 2.4 Hz, 1H, H-6), 7.20 (d, *J* = 8.4, 1H, H-5'), 2.19 (s, 3H, H₃). HRMS *m/z* calcd for C₁₄H₁₂FN₂OS (MH⁺), 275.0649; found, 275.0642.

Compound **10** was then dissolved in C₂H₅OH (100 μL), to which was added a solution of K₃Fe(CN)₆ (20 mg, 60 μmol).²² The resulting mixture was stirred at room temperature for 3 h and then diluted with H₂O (2 mL). The white precipitate (**11**) was collected by filtration. UV λ_{max} 362 nm. HRMS *m/z* calcd for C₁₄H₁₀FN₂OS (MH⁺), 273.0492; found, 273.0496.

Enzyme Preparations. Human P450s 1A1 and 2W1 were coexpressed with NADPH-P450 reductase, and P450s 2S1 and 2W1 were expressed in *Escherichia coli* membranes as previously described.^{5,23} Human P450 2S1 and 2W1 were purified as described.⁵ Human liver microsomes were prepared from 10 randomly chosen human liver donor samples using previously reported procedures.²⁴

Incubation Conditions. A typical incubation mixture for qualitative studies contained P450 enzyme (0.3–0.8 μM) in bacterial membranes or liver microsomes, an NADPH-generating system (10 mM glucose 6-phosphate, 0.5 mM NADP⁺, and 4 μg mL⁻¹ yeast glucose 6-phosphate dehydrogenase) and the substrate (100 μM) in 0.10 M potassium phosphate buffer (pH 7.4).²⁴ When a purified P450 was used, it was generally reconstituted with a 2-fold excess of NADPH-P450 reductase and 30 μM *L*-α-dilauroyl-*sn*-glycero-3-phosphocholine.^{5,7,24,33} The incubations were performed at 37 °C for 30–60 min. CH₂Cl₂ (2-fold volume) was added to terminate the reaction, and the resulting mixture was separated by centrifugation at 2 × 10³g for 5 min. The organic layer was transferred and dried under an N₂ stream. The residue was dissolved in CH₃CN for HPLC and liquid chromatography–mass spectrometry (LC-MS) analysis.

Large-scale reactions (total volume of 50–100 mL) were performed to obtain sufficient amounts of metabolites for NMR analysis. The incubation conditions were the same as in the qualitative studies except that catalase ($4 \mu\text{g mL}^{-1}$, Sigma Aldrich, from bovine erythrocytes, dialyzed before use to remove thymol) was also present in the mixture. The reactions were terminated by addition of CH_2Cl_2 (2-fold volume). The resulting mixtures were centrifuged at 2×10^3g for 5 min, and the lower layer of each was concentrated using a rotary evaporator. A minimum amount of CH_3CN was added to dissolve the residue, which was subsequently subjected to preparative HPLC isolation (vide infra).

Anaerobic Incubations. Anaerobic reduction experiments were performed in Thunberg tubes, with the samples deaerated with the use of a manifold, using alternating cycles of argon and vacuum (20 mmHg) (five cycles). A typical 500 μL incubation mixture contained 0.5 μM P450 2S1, 1.0 μM NADPH-P450 reductase, 160 μM L- α -1,2-dilauryl-*sn*-glycero-3-phosphocholine, 100 mM potassium phosphate buffer (pH 7.4), and 100 μM **10** (from a freshly prepared 10 mM DMSO stock). After 5 min of preincubation, an NADPH-generating system was added from the neck of the tube under anaerobic conditions. The reactions were incubated at 37°C for 45 min, terminated by the addition of 1 mL of CH_3CN , and analyzed by HPLC.

Steady-State Kinetic Measurements of P450 Reactions. The incubation conditions for kinetic studies were similar to those employed in the qualitative studies. The concentrations of P450 and the NADPH-generating system remained the same. Reactions with a series of different substrate concentrations ranging from 0 to 200 μM were carried out, in duplicate, at 37°C for 10 and 15 min for GW 610 with P450s 2W1 and 1A1, respectively, and for 15 and 25 min for 5F 203 with P450s 2W1 and 1A1, respectively. After the reactions were quenched with CH_2Cl_2 (2-fold volume), a small amount of internal standard (5-fluoro-2-(3-hydroxy-4-methoxyphenyl)-benzothiazole, **4b**, 5 μL , 0.1 mM for GW 610 reactions; 2-phenylbenzothiazole, **12**, 5 μL , 0.1 mM for 5F 203 reactions) was added to each reaction mixture. The mixture was centrifuged at 2×10^3g for 5 min, and the organic layer was transferred and dried under an N_2 stream. The residue was dissolved in CH_3CN for HPLC analysis, from which the P450 enzyme kinetic data (K_m and k_{cat}) were calculated using nonlinear regression analysis (Prism, GraphPad Software, La Jolla, CA).

GSH Adduct Formation from GW 610 and 5F 203 Oxidation Products. A typical incubation mixture (total volume of 0.50 mL) contained P450 enzyme (2W1, 1A1, or microsomes, 0.50 μM) in bacterial membranes or liver microsomes, an NADPH-generating system (10 mM glucose 6-phosphate, 0.5 mM NADP^+ , 4 $\mu\text{g mL}^{-1}$ yeast glucose 6-phosphate dehydrogenase), catalase ($4 \mu\text{g mL}^{-1}$), GSH (5 mM), and the substrate (100 μM) in 0.10 M potassium phosphate buffer (pH 7.4). The incubations were performed at 37°C for 12–15 h. CH_3CN (2-fold volume of incubation mixture) was added to terminate the reaction, and the supernatant was analyzed by LC-MS.

Formation of dGuo Adduct with Synthetic **10 and P450 2W1-Catalyzed Oxidation of 5F 203.** With Synthetic **10**. To a freshly prepared solution of **10** in CH_2Cl_2 (10 μM , 1.0 mL), 20 μL of Ac_2O was added. The mixture was swirled for 5 min, the solvent was removed in vacuo, and 30 μL of CH_3CN was added. The CH_3CN solution (5 μL) was added to a solution of 100 mM potassium phosphate buffer (pH 7.4) containing 0.1 mM EDTA (245 μL), followed by the addition of aqueous dGuo (250 μL of a 10 mM solution). The resulting mixture was incubated at 37°C under argon for 2 h and analyzed by LC-MS.

With the P450 2W1-Catalyzed Oxidation of 5F 203. 5F 203 was incubated with P450 2W1 membranes under the usual incubation conditions at 37°C for 45 min (total volume, 0.5 mL), the reaction was quenched by the addition of 1 mL of CH_2Cl_2 and mixed with a vortex device, and the organic layer was transferred. Ac_2O (20 μL) was added to the CH_2Cl_2 solution, which was swirled for 5 min and dried under an N_2 stream. CH_3CN (5 μL) and 100 mM potassium phosphate buffer (pH 7.4) containing 0.1 mM EDTA (245 μL) were added to the residue. The contents were mixed with a vortex device and added to a 10 mM aqueous solution of dGuo (250 μL). The

resulting mixture was incubated at 37°C under argon for 2 h and analyzed by LC-MS.

HPLC-UV Assays. HPLC analysis was performed on a Waters Acquity UPLC system equipped with two pumps, an autosampler, and a photodiode array detector (Waters). Samples for qualitative and kinetic studies were injected onto an octadecylsilane (C_{18}) reversed-phase column (5 μm , 2.1 mm \times 250 mm, Hypersil GOLD, Thermo Scientific, Odessa, TX). The column was maintained at room temperature. The eluting solvents used were mobile phase A ($\text{CH}_3\text{CN}:\text{H}_2\text{O}$, 5:95, 0.5% HCO_2H , v/v) and mobile phase B ($\text{CH}_3\text{CN}:\text{H}_2\text{O}$, 95:5, 0.5% HCO_2H , v/v). The flow rate was 0.5 mL min^{-1} . The gradient conditions for all of the qualitative and kinetic studies (except the kinetic analysis of the transformation of GW 610) started from 5% B (v/v) during the first 2 min (0–2 min) and was increased to 100% B over 5 min (2–7 min), maintained at that level for 4.5 min (7–11.5 min), and then returned to 5% B (v/v) over 0.5 min (11.5–12 min) before equilibration (12–15 min). 5-Fluoro-2-(3-hydroxy-4-methoxyphenyl)-benzothiazole (**4b**) was used as the internal standard in the kinetic analysis of the oxidation of GW 610. The separation of the products, internal standard, and parent compound was achieved using gradient conditions as follows: 30% B (v/v) during the first 2 min (0–2 min), increased to 65% B (v/v) over 10 min (2–12 min), then decreased to 30% B (v/v) over 1 min (12–13 min) before equilibration (13–15 min). Some products were identified by comparison with their retention times, UV spectra, and LC-MS with corresponding reference compounds (vide infra).

Isolation of metabolites was performed using a Hitachi L-7100 HPLC system (Tokyo, Japan) equipped with a single pump and UV detector (LDC Spectro Monitor III Model 1204D, Thermo). Samples (typical injection 100–150 μL) were injected onto a semipreparative octadecylsilane (C_{18}) reversed-phase column (5 μm , 10 mm \times 250 mm, Prodigy, Phenomenex, Torrance, CA). The column was maintained at room temperature. The eluting solvents used were the same as used for analytical HPLC analysis, mobile phase A ($\text{CH}_3\text{CN}:\text{H}_2\text{O}$, 5:95, 0.5% HCO_2H , v/v) and mobile phase B ($\text{CH}_3\text{CN}:\text{H}_2\text{O}$, 95:5, 0.5% HCO_2H , v/v). The flow rate was 4 mL min^{-1} . Isocratic elution (65% B, v/v) was used for isolation of **4c'**. The gradient for isolation of **8a** and **8b** started from 60% B (v/v), was increased to 70% B (v/v) over 10 min (0–10 min), and then returned to 60% B (v/v) in 2 min (10–12 min) before equilibration (12–20 min). The fractions containing products of interest were collected, and CH_3CN was removed under a stream of N_2 . The resulting mixture was extracted with CH_2Cl_2 three times, and the combined organic layers were dried over Na_2SO_4 . CH_2Cl_2 was removed under a stream of N_2 , and the residue was dissolved in CDCl_3 for NMR analysis.

LC-MS Analysis. LC/MS and LC/MS/MS analyses were performed on Finnigan LTQ ion trap mass spectrometers (Thermo Fisher Scientific, San Jose, CA). The samples were analyzed in the electrospray ionization (ESI) positive ion mode. A Waters Acquity UPLC system was coupled with the mass spectrometer. An octadecylsilane (C_{18}) reversed-phase column (5 μm , 2.1 mm \times 250 mm, Hypersil GOLD, Thermo Scientific) was used and was maintained at room temperature in the analyses. The eluting solvents used were mobile phase A ($\text{CH}_3\text{CN}:\text{H}_2\text{O}$, 5:95, 0.5% HCO_2H , v/v) and mobile phase B ($\text{CH}_3\text{CN}:\text{H}_2\text{O}$, 95:5, 0.5% HCO_2H , v/v). The flow rate was 0.5 mL min^{-1} . The gradient conditions were the same as described above: 5% B (v/v) during the first 2 min (0–2 min), and increased to 100% B (v/v) in 5 min (2–7 min), maintained at that level for 4.5 min (7–11.5 min), and then returned to 5% B (v/v) in 0.5 min (11.5–12 min) before equilibration (12–15 min). MS conditions (N_2 gas flow, spray current, voltages, etc.) were tuned to give maximum sensitivity for the parent compound.

LC-HRMS was performed on a Waters Acquity UPLC system coupled with a Waters Synapt hybrid quadrupole/OA-TOF mass spectrometer (Waters). The samples were analyzed in the ESI positive ion mode. The MS conditions were tuned to give maximum sensitivity for the parent compound. The LC conditions were the same as in the LC-MS studies (vide supra).

RESULTS

Incubations of 2-Phenylbenzothiazole, GW 610, and 5F 203 with P450 2W1 and 2S1: Preliminary Assays. No products were observed following the incubation of 2-phenylbenzothiazole with reconstituted systems containing recombinant human P450 2W1 or 2S1. In addition, no products were observed by HPLC-UV following the incubation of either GW 610 or 5F 203 with P450 2S1. Products were formed in the incubation of GW 610 or 5F 203 with P450 2W1, as judged by HPLC-UV assays.

Hydroxylation and Demethylation of GW 610 by P450s 2W1 and 1A1. An HPLC peak appeared at retention time (t_R) 6.05 min in the incubation of GW 610 (t_R 6.55 min) with P450 2W1 (Figure 1B). Further LC-MS analysis showed




Figure 1. HPLC chromatograms of GW 610 oxidation products formed with P450s 1A1 and 2W1. (A) Incubation products of GW 610 formed with P450 1A1 (45 min). (B) Incubation products of GW 610 formed with P450 2W1 (45 min). (C) Chemically synthesized **4c**. (D) Synthetic **4b**. (E) Incubation products of GW 610 formed with P450 2W1 (60 min). (F) Incubation products of **4c** formed with P450 2W1 (60 min).

that the peak had m/z 276 (Figure S9 in the Supporting Information) possibly corresponding to a demethylated product. To determine the structure of the product, two chemicals were synthesized as potential products (**4b** and **4c**, Scheme 1A). Comparison of synthetic **4b** and **4c** with the incubation mixture using HPLC showed cochromatography with **4c** (t_R 6.05 min, Figure 1C), whereas **4b** was eluted slightly earlier (t_R 5.98 min, Figure 1D) under the same conditions. The t_R 6.05 min peak was also the predominant peak obtained from the incubation of GW 610 with P450 1A1 (Figure 1A).

Using more P450 2W1 and a longer incubation time, a new peak appeared at t_R 5.55 min (Figure 1E). In a separate experiment, **4c** was incubated with P450 2W1 and also yielded

the t_R 5.55 min peak as a single product (Figure 1F). LC-MS analysis indicated that the peak had an m/z of 292 (MH^+ , Figure S9 in the Supporting Information), 2 Da greater than GW 610 and 16 Da greater than **4c**, suggesting that it might be a secondary oxidation metabolite. A sufficient amount of **4c'** was obtained from a large-scale incubation of **4c** with P450 2W1 for NMR analysis. In the 1D 1H NMR spectrum of **4c'** (Figure S2 in the Supporting Information), one high field proton signal disappeared in the aromatic region and the two doublet proton signal (in **4c**) was replaced with two singlet proton signals (in **4c'** at 7.27 and 7.34 ppm), suggesting substitution at 5' position. The proton coupling pattern on the fluorine-containing ring was unchanged [2D total correlation (NMR) spectroscopy (TOCSY) results, Figure 2], supporting this conclusion. Compound **4c'** was assigned the structure shown in Scheme 2, based on both the LC-MS and the NMR.






Figure 2. TOCSY spectrum of **4c'** in $CDCl_3$ (600 MHz).

Oxidation of 5F 203 by P450 2W1, 1A1, and Human Liver Microsomes. Two product peaks appeared at t_R 5.45 min (**8a**, UV λ_{max} 343 nm) and 6.02 min (**10**, UV λ_{max} 339 nm) following incubation of 5F 203 (t_R 6.31 min, UV λ_{max} 347 nm) with P450 2W1 (Figure S7A in the Supporting Information). LC-MS results showed that both peaks had an m/z 275 ion ($[MH]^+$), 16 Da greater than the parent compound 5F 203, very likely corresponding to oxidation products. Two product peaks also appeared at t_R 5.45 min (**8a**, UV λ_{max} 343 nm) (which was present in the P450 2W1 oxidation as well) and t_R 5.80 min (**8b**, UV λ_{max} 356 nm) from the incubation of 5F 203 (t_R 6.31 min) with P450 1A1 (Figure S7B in the Supporting Information). Interestingly, the HPLC results for the incubation of 5F 203 with human liver microsomes showed all three major products (**8a**, **8b**, and **10**). LC-MS showed that all three peaks had m/z 275. Arylamines are known to undergo oxidation to form hydroxylamines and nitroso and nitro compounds,²⁵ in addition to hydroxylation on the aromatic rings. The hydroxylamine (**10**), nitroso (**11**), and nitro (**9**) derivatives of 5F 203 were readily synthesized. The t_R values of **10**, **11**, and **9** were 6.04, 7.43, and 7.11 min, respectively, under the same conditions. The t_R and the UV spectrum of synthetic **10** were identical to those of oxidation product **10** found in the 5F 203 incubation with P450 2W1. A mass signal (m/z 273, $[MH]^+$) corresponding to the nitroso derivative (**11**) was observed, consistent with the t_R (7.49 min) in LC-MS. However, no signal for the nitro derivative (**9**) was detected.

Scheme 2. P450 2W1, P450 1A1, and Microsomal GW 610 Reactions



Scheme 3. P450 2W1, P450 1A1, and Microsomal 5F 203 Reactions



Compound **10** was also detected following incubation of 5F 203 with P450 1A1, and **8b** was detected as well in incubations of 5F 203 with P450 2W1, respectively, both as minor products (Figure S10 in the Supporting Information). A large-scale incubation of 5F 203 with human liver microsomes provided sufficient amounts of **8a** and **8b** for NMR spectra [the instability and poor solubility of **10** in common organic solvents (e.g., CHCl_3 , CH_2Cl_2 , and CH_3OH) complicated the use of NMR for comparison]. In the 1D ^1H NMR of **8a** (Figure S3 in the Supporting Information), the retention of the two pairs of doublet signals at δ 7.84 and 6.76 ppm and the disappearance of a singlet proton signal clearly indicated the presence of a nonhydrogen substituent at 2'-position. Additionally, the homonuclear correlated (NMR) spectroscopy (COSY) NMR spectrum of **8a** (Figure S3 in the Supporting Information) showed an unambiguous coupling relationship between the two pairs of doublet signals at δ 7.84 and 6.76 ppm, providing further evidence for 2'-substitution. Given the LC-MS results, the structure **8a** was proposed, that is, a 2'-hydroxy derivative of 5F 203 (Scheme 3). In the ^1H NMR spectrum of **8b** (Figure S4 in the Supporting Information), the proton signal splitting pattern was similar to that of **4c'**, where one high field aromatic

proton signal disappeared and two singlet proton signals replaced the original doublets in the precursors. On the basis of the LC-MS and NMR data available, the structure **8b** was assigned, that is, the 5'-hydroxy product of 5F 203 (Scheme 3).

Steady-State Kinetic Data for P450 2W1 and 1A1 Oxidation Reactions. Steady-state kinetic results for P450 2W1- and 1A1-catalyzed oxidation reactions with GW 610 and 5F 203 are summarized in Table 1, including the formation of **4c** from GW 610 catalyzed by P450 2W1 and 1A1, the formation of **8a** and **10** from 5F 203, and the formation of **8a**

Table 1. Steady-State Kinetics of P450 2W1- and 1A1-Catalyzed Reactions

substrate	P450	product	K_m (μM)	k_{cat} (min^{-1})	k_{cat}/K_m ($\mu\text{M}^{-1}\text{min}^{-1}$)
GW 610	2W1	4c	22 ± 7	3.8 ± 0.4	0.18 ± 0.05
	1A1	4c	10 ± 3	0.37 ± 0.03	0.036 ± 0.01
5F 203	2W1	8a	31 ± 11	0.95 ± 0.1	0.030 ± 0.01
		10	35 ± 12	0.56 ± 0.06	0.016 ± 0.005
	1A1	8a	32 ± 9	1.7 ± 0.2	0.054 ± 0.02
		8b	29 ± 8	3.1 ± 0.3	0.11 ± 0.03




Figure 3. LC-MS and LC-MS/MS chromatograms and CID spectra showing the presence of a GSH conjugate of GW 610 formed with P450 2W1. (A) Extracted ion chromatogram of m/z 597. (B) LC-MS spectrum of the peak at t_R 4.48 min. (C) Product ion chromatogram of m/z 597. (D) LC-MS/MS spectrum of the peak at t_R 4.45 min.




Figure 4. LC-MS and LC-MS/MS chromatograms and CID spectra showing the presence of a GSH conjugate of 5F 203 formed with P450 2W1. (A) Extracted ion chromatogram of m/z 580. (B) LC-MS spectrum of the peak at t_R 4.62 min. (C) Product ion chromatogram of m/z 580. (D) LC-MS/MS spectrum of the peak at t_R 4.60 min.

and **8b** from 5F 203. P450 2W1 was 5-fold more efficient than P450 1A1 in the formation of **4c** from GW 610. In contrast, P450 1A1 was ~2-fold more efficient than P450 2W1 in terms of oxidation of 5F 203 to form **8a**. In addition, while P450 2W1 catalyzed 5F 203 to yield the hydroxylamine **10**, P450 1A1 oxidized 5F 203 to **8b** much more efficiently.

GSH Adduct Formation from GW 610 and 5F 203 Oxidation Products. A peak at t_R ~ 4.5 min appeared in total ion chromatograms (ESI⁺) of all LC-MS analyses for incubation mixtures of GW 610 with P450 2W1 (Figure 3A), P450 1A1, or human liver microsomes (data not shown) in the presence of

GSH. The MS of that peak (m/z 597, Figure 3B) was consistent with the structure **4g** (the GSH conjugate of **4c'**), and another significant signal in the MS spectrum (m/z 299, Figure 3B) was determined to be a doubly charged GSH conjugate ($[M + 2H]^+$), in that its fragmentation pattern was found to be identical that of the peak (m/z 597) (data not shown). The LC-MS/MS of the peak at t_R ~ 4.5 min (Figure 3C) gave two major fragment ions: m/z 468 (loss of 129) and 324 (loss of 273), commonly seen for GSH conjugates (Figure 3D).




Figure 5. LC-MS/MS and LC-MS³ chromatograms and CID spectra showing a dGuo adduct of an oxidation product of SF 203 formed with P450 2W1. (A) Extracted ion chromatogram of m/z 408. (B) LC-MS/MS spectrum of the peak at t_R 4.63 min. (C) Total ion chromatogram of CID of the m/z 408 product ion. (D) LC-MS³ spectrum of the peak at t_R 4.61 min.

Similarly, the LC-MS total ion chromatograms for reactions of SF 203 with P450 2W1 and GSH (Figure 4A), as well as P450 1A1 or human liver microsomes (data not shown) in the presence of GSH, all showed a peak at $t_R \sim 4.6$ min under the same conditions as for GW 610. The peak had m/z 580 (Figure 4B), consistent with **8g** (the GSH conjugate of **8b**), and the predominant signal in the MS spectrum (m/z 290.6, Figure 4B) was also proven to be a doubly charged GSH conjugate ($[M + 2H]^+$) upon comparison of its fragmentation pattern with the peak (m/z 580) (data not shown). LC-MS/MS analysis of the peak (m/z 580, Figure 4C) again showed two major fragment ions: m/z 451 (loss of 129) and 307 (loss of 273), providing supportive evidence for the formation of a GSH conjugate (Figure 4D).

Formation of a dGuo Adduct with Synthetic 10 and a P450 2W1-Catalyzed Oxidation of SF 203. The analyses of samples of dGuo incubated with synthetic **10** and the oxidation product of SF 203 formed by P450 2W1 (using LC-MS in the positive ion mode) both showed a peak at t_R 4.6 min with m/z 524 (MH^+), which is consistent with a dGuo adduct of compound **10**. From the reaction of SF 203 P450 2W1 incubation products with dGuo, CID of the peak at t_R 4.6 min (Figure 5A, positive ion mode) yielded a characteristic transition of m/z 524 \rightarrow 408 (Figure 5B), with a loss of 116, very typical of dGuo adducts. LC-MS³ of m/z 408 (Figure 5C) generated a fragment ion with m/z 391 (loss of NH_3) as the major peak (Figure 5D), consistent with the proposed

structure, providing evidence for the presence of a dGuo adduct. The LC-MS/MS and LC-MS³ analyses of the sample of synthetic **10** with dGuo showed identical fragmentation results (Figure S11 in the Supporting Information) with those found for SF 203/P450 2W1 incubation products reacting with dGuo.

Anaerobic Reduction of 10 Catalyzed by P450 2S1. Freshly prepared **10** was incubated with P450 2S1 under anaerobic conditions (Figure 6A) and normal aerobic conditions (Figure 6B), in parallel. The peaks appearing at t_R 6.02, 6.33, and 7.41 min correspond to **10**, SF 203, and **11**, respectively. When authentic **10** was incubated in 100 mM potassium phosphate buffer (pH 7.4) containing 0.1 mM EDTA for 45 min, varying amounts of **11** (Figure 6A-b,B-b) were formed by oxidation. More **11** was formed under aerobic conditions. In contrast, SF 203 was produced from the reduction of **10** under both anaerobic and aerobic conditions with P450 2S1 in the presence of NADPH-P450 reductase and an NADPH-generating system (Figure 6A-c,B-c, respectively). More SF 203 was formed under anaerobic conditions. With only the NADPH-generating system deleted, oxidation of **10** to **11** occurred under both anaerobic (Figure 6A-d) and aerobic conditions (Figure 6B-d), and unidentified products were also formed, especially under aerobic conditions (t_R 7.90 min and others, Figure 6B-d). With **10**, NADPH-P450 reductase, and the NADPH-generating system in buffer (but in the absence of P450 2S1), oxidation yielded only barely observable amounts of





Figure 6. Reduction of **10** by P450 2S1. Freshly prepared **10** ($5 \mu\text{L}$ of a 10 mM solution in DMSO) was incubated with P450 2S1 (total volume 0.5 mL) at $37 \text{ }^\circ\text{C}$ for 45 min under anaerobic (A) and normal aerobic conditions (B). (a) Standard **10**. (b) Standard **10** in 100 mM potassium phosphate buffer (pH 7.4) containing 0.1 mM EDTA, incubated at $37 \text{ }^\circ\text{C}$ for 45 min . (c) Standard **10** incubated with P450 2S1 in the presence of NADPH-P450 reductase and an NADPH-generating system. (d) Standard **10** incubated with all typical components of the P450 2S1 system with the exception of the NADPH-generating system. (e) Standard **10** incubated with all P450 system components with the exception of P450 2S1.

Scheme 4. GSH Conjugates of GW 610 and 5F 203 Oxidation Products



11 under both anaerobic (Figure 6A-e) and normal aerobic conditions (Figure 6B-e).

DISCUSSION

In this study, we characterized the P450-mediated bioactivation of GW 610 and 5F 203 to form reactive intermediates, which may lead to their antitumor activity within sensitive tumor cells.^{13,20} Our results clearly demonstrate that, in addition to P450 1A1, P450 2W1 is also involved in the biotransformation of GW 610. Consistent with a previous hypothesis,¹¹ O-demethylation is the first step of the process, and it occurred in a regiospecific manner to give **4c** as the single initial product. Furthermore, steady-state kinetic studies indicated that P450 2W1 has a 5-fold higher catalytic efficiency toward GW 610 as compared to P450 1A1. This result may explain the observation in a previous study that the addition of the P450 1A1 inhibitor resveratrol²⁶ did not affect the potency of GW 610 in sensitive cell lines,¹⁹ because P450 2W1 could also contribute to its metabolism. The result may also explain the potent selective antitumor activity of GW 610 in human colon cancer cells, where P450 2W1 was found to be selectively expressed.^{8,9} Further oxidation of **4c** leads to the formation of a catechol, **4c'**, which can be readily oxidized to an *o*-quinone and react with GSH (Scheme 4).

5F 203 can be oxidized by P450 1A1 as well as 2W1, and the products differ. The two major products of P450 1A1-catalyzed oxidation of 5F 203 were **8a** and **8b**, both formed by hydroxylations on one aromatic ring. While **8a** was also one of the two major products formed by P450 2W1, another product was the hydroxylamine **10**, which had been previously proposed as a putative 5F 203 bioactivation product but not characterized.^{27,28} A compound analogous to **10** (with no F and methyl groups) was shown to be able to bind to purines and pyrimidines via a nitrenium ion intermediate^{28,29} (the mechanism for the formation of C⁸-substituted dGuo-arylamine adduct was reported previously³⁰). To our knowledge, our *in vitro* results constitute the first evidence of the formation of **10** in the bioactivation of 5F 203, and indeed, LC-MS results provide the evidence for the formation of dGuo adduct with activated **10** (Figure 5). The nitroso derivative (**11**) was also detected in LC-MS (Figure S10 in the Supporting Information).

Among the 2-aryl-benzothiazoles tested in this study, all of the substrates of P450 2W1 contain at least one hydrogen-bonding donor ($-\text{NH}_2$, 5F203), acceptor ($-\text{OCH}_3$, GW 610), or both ($-\text{OCH}_3$, $-\text{OH}$, **4c**). In contrast, the 2-phenyl-benzothiazole, without a hydrogen-bonding donor or acceptor as a substituent on the aromatic ring, is not a substrate for P450 2W1.

The formation of GSH conjugates is usually considered as evidence for chemically reactive intermediates, often associated with drug toxicity and potential adverse drug reactions.³¹ The GW 610 GSH conjugate is presumably formed via a 1,2-quinone intermediate (Scheme 4A), whereas the 5F 203 GSH conjugate is presumably formed via a quinoneimine (Scheme 4B). The hydroxylamine generated in the biotransformation of 5F 203 could react with dGuo to produce an adduct via a nitrenium ion intermediate, in a similar way as shown in studies using a 5F 203 analogue^{28,29} or other carcinogenic arylamines.²⁵

Neither GW 610 nor 5F 203 was a substrate for P450 2S1, that is, no products were observed from the incubations. However, as shown in the incubation of hydroxylamine **10** with P450 2S1, reduction of **10** to 5F 203 occurred under both anaerobic and aerobic conditions—more so under anaerobic conditions (Figure 6A-c)—decreasing the production of

nitrenium ions and formation of dGuo adducts and thus alleviating the damage caused by 5F 203. These results can explain the role of P450 2S1 in attenuating the antitumor activity of 5F 203, a conclusion reached only on the basis of knock-down experiments.²⁰ It is worth noting that NADPH-P450 reductase appeared to be able to reduce the nitroso derivative **11** (to **10**) both anaerobically and aerobically, consistent with similar observations in a previous study of the nitroso derivative of 2-amino-3-methylimidazo[4,5-*f*]quinoline.³²

In conclusion, the biotransformation pathways of the antitumor agents GW 610 and 5F 203 involving human P450s 1A1, 2W1, and 2S1 were studied, and the chemical structures of major products were determined. The high catalytic efficiency of P450 2W1 for oxidation of GW 610 may explain the potent and selective antitumor activity to colon cancer cells. The hydroxylamine **10** was identified, for the first time, as a major oxidation product of 5F 203 formed by P450 2W1, which can further react with dGuo to form an adduct (Figure 5). P450 2S1 can catalyze the reduction of **10** back to 5F 203 under anaerobic conditions and (to a lesser extent) aerobic conditions, thus resulting in attenuating the anticancer activity by decreasing the production of nitrenium ions and thus the level of the dGuo adduct and probably other DNA adducts. Oxidation products of GW 610 and 5F 203 can form GSH conjugates, presumably via quinone and quinoneimine intermediates, which may lead to their pharmacological and possible toxicological consequences.

ASSOCIATED CONTENT

Supporting Information

Selective NOE NMR spectra of GW 610, ¹H NMR spectrum of **4c'**, ¹H NMR and HH COSY spectra of **8a**, ¹H NMR spectrum of **8b**, UV spectra of GW610, **4b**, **4c**, and **4c'**, HPLC chromatograms of incubations of GW 610 with P450 2W1 using **4b** as internal standard, HPLC chromatograms of incubations of 5F 203 with P450s 2W1 and 1A1, HPLC chromatograms and UV spectra of synthetic **10**, **11**, and **9**, LC-MS chromatograms and spectra of **4c** and **4c'**, LC-MS chromatograms of 5F 203 oxidation products catalyzed by P450s 2W1 and 1A1, and LC-MS/MS and LC-MS³ chromatograms and CID spectra showing the presence of the dGuo adduct formed with synthetic **10**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*Tel: 615-322-2261. Fax: 615-322-4349. E-mail: f.guengerich@vanderbilt.edu.

Funding

This work was supported in part by the U.S. Public Health Service (F.P.G., R37 CA090426, P30 ES000267).

Notes

The authors declare no competing financial interest.

ABBREVIATIONS

5F 203, 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole; COSY, correlated (NMR) spectroscopy; ESI, electrospray ionization; GW 610, 5-fluoro-2-(3,4-dimethoxyphenyl)-benzothiazole; LC-MS, liquid chromatography–mass spectrometry; NOE, nuclear Overhauser effect; TOCSY, total correlation

(NMR) spectroscopy; UPLC, ultra performance liquid chromatography

REFERENCES

- (1) Guengerich, F. P. (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. *Chem. Res. Toxicol.* 14, 611–650.
- (2) Guengerich, F. P. (2008) Cytochrome P450 and chemical toxicology. *Chem. Res. Toxicol.* 21, 70–83.
- (3) Guengerich, F. P. (2005) Human cytochrome P450 enzymes. In *Cytochrome P450: Structure, Mechanism, and Biochemistry*, 3rd ed. (Ortiz de Montellano, P. R., Ed.) pp 377–530, Kluwer Academic/Plenum Press, New York.
- (4) Guengerich, F. P., and Cheng, Q. (2011) Orphans in the human cytochrome P450 superfamily: Approaches to discovering functions and relevance in pharmacology. *Pharmacol. Rev.* 63, 684–699.
- (5) Wu, Z. L., Sohl, C. D., Shimada, T., and Guengerich, F. P. (2006) Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. *Mol. Pharmacol.* 69, 2007–2014.
- (6) Nishida, C. R., Lee, M., and Ortiz de Montellano, P. R. (2010) Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1. *Mol. Pharmacol.* 78, 497–502.
- (7) Xiao, Y., Shinkyu, R., and Guengerich, F. P. (2011) Cytochrome P450 2S1 is reduced by NADPH-cytochrome P450 reductase. *Drug Metab. Dispos.* 39, 944–946.
- (8) Gomez, A., Karlgren, M., Edler, D., Bernal, M. L., Mkrтчian, S., and Ingelman-Sundberg, M. (2007) Expression of CYP2W1 in colon tumors: Regulation by gene methylation. *Pharmacogenomics* 8, 1315–1325.
- (9) Gomez, A., Nekvindova, J., Travica, S., Lee, M. Y., Johansson, I., Edler, D., Mkrтчian, S., and Ingelman-Sundberg, M. (2010) Colorectal cancer-specific cytochrome P450 2W1: Intracellular localization, glycosylation, and catalytic activity. *Mol. Pharmacol.* 78, 1004–1011.
- (10) Edler, D., Stenstedt, K., Ohrling, K., Hallstrom, M., Karlgren, M., Ingelman-Sundberg, M., and Raynhammar, P. (2009) The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer—A pilot study. *Eur. J. Cancer* 45, 705–712.
- (11) Aiello, S., Wells, G., Stone, E. L., Kadri, H., Bazzi, R., Bell, D. R., Stevens, M. F., Matthews, C. S., Bradshaw, T. D., and Westwell, A. D. (2008) Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). *J. Med. Chem.* 51, 5135–5139.
- (12) Hutchinson, I., Chua, M. S., Browne, H. L., Trapani, V., Bradshaw, T. D., Westwell, A. D., and Stevens, M. F. (2001) Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. *J. Med. Chem.* 44, 1446–1455.
- (13) Brantley, E., Trapani, V., Alley, M. C., Hose, C. D., Bradshaw, T. D., Stevens, M. F., Sausville, E. A., and Stinson, S. F. (2004) Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells. *Drug Metab. Dispos.* 32, 1392–1401.
- (14) Chua, M. S., Kashiyama, E., Bradshaw, T. D., Stinson, S. F., Brantley, E., Sausville, E. A., and Stevens, M. F. G. (2000) Role of CYP1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. *Cancer Res.* 60, 5196–5203.
- (15) Trapani, V., Patel, V., Leong, C. O., Ciolino, H. P., Yeh, G. C., Hose, C., Trepel, J. B., Stevens, M. F., Sausville, E. A., and Loaiza-Perez, A. I. (2003) DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (SF 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells. *Br. J. Cancer* 88, 599–605.
- (16) Omiecinski, C. J., Redlich, C. A., and Costa, P. (1990) Induction and developmental expression of cytochrome-P4501A1 messenger-RNA in rat and human tissues—Detection by the polymerase chain-reaction. *Cancer Res.* 50, 4315–4321.
- (17) Kitada, M., Taneda, M., Itahashi, K., and Kamataki, T. (1991) 4 forms of cytochrome-P-450 in human fetal liver—Purification and their capacity to activate promutagens. *Jpn. J. Cancer Res.* 82, 426–432.
- (18) Leong, C. O., Suggitt, M., Swaine, D. J., Bibby, M. C., Stevens, M. F., and Bradshaw, T. D. (2004) In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles. *Mol. Cancer Ther.* 3, 1565–1575.
- (19) Mortimer, C. G., Wells, G., Crochard, J. P., Stone, E. L., Bradshaw, T. D., Stevens, M. F., and Westwell, A. D. (2006) Antitumor benzothiazoles. 26.¹ 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines. *J. Med. Chem.* 49, 179–185.
- (20) Tan, B. S., Tiong, K. H., Muruhadas, A., Randhawa, N., Choo, H. L., Bradshaw, T. D., Stevens, M. F., and Leong, C. O. (2011) CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells. *Mol. Cancer Ther.* 10, 1982–1992.
- (21) Turesky, R. J., Lang, N. P., Butler, M. A., Teitel, C. H., and Kadlubar, F. F. (1991) Metabolic-activation of carcinogenic heterocyclic aromatic amines by human liver and colon. *Carcinogenesis* 12, 1839–1845.
- (22) Peng, L. J., and Turesky, R. J. (2011) Mass spectrometric characterization of 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine *N*-oxidized metabolites bound at Cys(34) of human serum albumin. *Chem. Res. Toxicol.* 24, 2004–2017.
- (23) Parikh, A., Gillam, E. M., and Guengerich, F. P. (1997) Drug metabolism by *Escherichia coli* expressing human cytochromes P450. *Nat. Biotechnol.* 15, 784–788.
- (24) Guengerich, F. P., and Bartleson, C. J. (2007) Analysis and characterization of enzymes and nucleic acids. In *Principles and Methods of Toxicology*, 5th ed. (Hayes, A. W., Ed.) pp 1981–2048, CRC Press, Boca Raton, FL.
- (25) Kim, D., and Guengerich, F. P. (2005) Cytochrome P450 activation of arylamines and heterocyclic amines. *Annu. Rev. Pharmacol. Toxicol.* 45, 27–49.
- (26) Chun, Y. J., Kim, M. Y., and Guengerich, F. P. (1999) Resveratrol is a selective human cytochrome P450 1A1 inhibitor. *Biochem. Biophys. Res. Commun.* 262, 20–24.
- (27) Chakraborty, M., Jin, K. J., Brewer, S. C., Peng, H. L., Platz, M. S., and Novak, M. (2009) Indirect and direct detection of the 4-(benzothiazol-2-yl)phenylnitrenium ion from a putative metabolite of a model anti-tumor drug. *Org. Lett.* 11, 4862–4865.
- (28) Novak, M., and Chakraborty, M. (2011) Reactions of a putative metabolite of the model antitumor drug 2-(4-aminophenyl)benzothiazole with purines and pyrimidines. *J. Phys. Org. Chem.* 24, 960–968.
- (29) Chakraborty, M., Jin, K. J., Glover, S. A., and Novak, M. (2010) Characterization of the 4-(benzothiazol-2-yl)phenylnitrenium ion from a putative metabolite of a model antitumor drug. *J. Org. Chem.* 75, 5296–5304.
- (30) Humphreys, W. G., Kadlubar, F. F., and Guengerich, F. P. (1992) Mechanism of C8 alkylation of guanine residues by activated arylamines: Evidence for initial adduct formation at the N7 position. *Proc. Natl. Acad. Sci. U.S.A.* 89, 8278–8282.
- (31) Park, B. K., Boobis, A., Clarke, S., Goldring, C. E., Jones, D., Kenna, J. G., Lambert, C., Lavery, H. G., Naisbitt, D. J., Nelson, S., Nicoll-Griffith, D. A., Obach, R. S., Routledge, P., Smith, D. A., Tweedie, D. J., Vermeulen, N., Williams, D. P., Wilson, I. D., and Baillie, T. A. (2011) Managing the challenge of chemically reactive metabolites in drug development. *Nat. Rev. Drug Discovery* 10, 292–306.
- (32) Kim, D. H., Kadlubar, F. F., Teitel, C. H., and Guengerich, F. P. (2004) Formation and reduction of aryl and heterocyclic nitroso

compounds and significance in the flux of hydroxylamines. *Chem. Res. Toxicol.* 17, 529–536.

(33) Xiao, Y., and Guengerich, F. P. (2012) Metabolomic analysis and identification of a role for the orphan human cytochrome P450 2W1 in selective oxidation of lysophospholipids. *J. Lipid Res.* DOI: 10.1194/jlr.M027185.